GET HELP NOW

Saturday, April 28, 2018

Biomarkers and efficacy of vaccine responses among patients treated with new MS drug

https://ift.tt/eA8V8J In March 2017, the US Food and Drug Administration approved ocrelizumab as the first treatment for both relapsing (RMS) and progressive forms of multiple sclerosis (MS), a genetic disease that afflicts approximately 400,000 Americans with an estimated 10,000 new cases every year. Neurologists have now looked more deeply into the impact of ocrelizumab in these patients.

from https://ift.tt/2JALOZC
via IFTTT
at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Children whose mothers use marijuana are more likely to try it at younger age

When mothers use marijuana during the first 12 years of their child's life, their cannabis-using children are more likely to start at an...